JPRN-UMIN000006755已完成未知
A dandomized phase ll study consisting S-1 + CDDP (SP) and Capecitabin + CDDP (XP) for adversed/metastatic gastric cancer with mesurable lesions and HER2 negative tumor (HERBIS-4A) (OGSG 1105) - HER2 Based Strategy in Stomac Cancer (HERBIS-4A) (OGSG 1105)
Osaka Gastrointestinal cancer chemotherapy Study Group (OGSG)0 个研究点目标入组 84 人开始时间: 2011年11月21日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 84
研究概览
简要总结
Response rate did not differ significantly between the capecitabine-cisplatin and S-1-cisplatin groups. S-1-cisplatin tended to confer a better progression-free survival, overall survival, and time to treatment failure compared with capecitabine-cisplatin. Common hematologic toxicities occurred in both groups. Anorexia, fatigue, and hyponatremia occurred more frequently in the capecitabine-cisplatin group.
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1)with prior chemotherapy and/or radiation therapy 2)with active double cancer(*) *simultaneous double cancer or sequential double cancer whose interstitial period is shorter than 5 years. Carcinoma in situ or Cancers localized in membranous layer are not included to double cancer. 3)with symptoms of brain metastasis 4)with history of severe allergy against medicines 5)with following diseases a)uncontrolled DM b)uncontrolled high-blood pressure c)liver cirrhosis and/or liver failure d)renal failure e)interstitial pneumonitis, pulmonary fibrosis, severe athelectasis f)active infection diseases g)heart failure, cardic infarction and/or severe disorder on ECG during recent 6 months 6)HBs positive status 7)with severe diarrhea (watery stool over 4 times a day) 8)patients who have flucytosine, fenitoin or walfarin 9)patients who have steroids continuously 10)women pregnant or women who like to be pregnant or males who like to have their own baby 11)patients decided not to register to this study due to psychologic diseases and/or psychological symptoms 12)patients whom doctor decide not ro register to this study
研究者
相似试验
已完成
2 期
S-1 and cisplatin with radiotherapy followed by durvalumab for locally advanced lung cancerung cancerLung cancerJPRN-jRCTs031190127Tanzawa Shigeru59
已完成
1 期
Phase I/II study of cisplatin and S-1 with concurrent thoracic radiation therapy for inoperable locally advanced non-small-cell lung cancer (OLCSG 0501)inoperable locally advanced non-small-cell lung cancerJPRN-C000000079Okayama Lung Cancer Study Group60
已完成
1 期
Phase I/ II study of S-1 and cisplatin with concurrent radiotherapy for locally advanced non-small-cell lung cancer.ung cancerJPRN-UMIN000005389ational Cancer Center Hospital East45
已完成
2 期
A phase II study of S-1 plus cisplatin with concurrent radiation for locally advanced thymic carcinoma (LOGIK1605/JART-1501)Thymic carcinomaJPRN-UMIN000024643Clinical Research Support Center Kyushu30
已完成
3 期
S-1 versus capecitabine in the first line treatment of metastatic colorectal cancer patients, the SALTO randomised phase III study of the Dutch Colorectal Cancer Group. A safety evaluation of oral fluoropyrimidines.Bowel CancerColorectalcancer10017991NL-OMON41674Dutch Colorectal Cancer Group160